Refine by
Vascular Disease Articles & Analysis: Older
58 news found
These new Circulatory System Tissue Microarrays, including Heart & Vascular Tissue Microarrays and Spleen Tissue Microarrays, are designed to accelerate research into heart disease, vascular disorders, and other conditions affecting the circulatory system. ...
Selective photothermolysis The theoretical basis of IPL skin treatment machine of skin diseases is the principle of selective photothermal action. Because IPL has a broad spectrum, it can cover multiple absorption peaks of various pigment groups such as melanin, oxidized hemoglobin, and water. In the treatment of vascular skin diseases, ...
Retinopathy of prematurity is a vascular disease of the immature retina of preterm babies, characterized by incomplete vessel growth which triggers elevated intraocular levels of vascular growth factor (VEGF) and abnormal vessel growth. ...
ByBayer AG
His main areas of research are imaging of abdominal organs and cardio-vascular diseases, molecular imaging and population imaging. Dr. Krestin is presently the Scientific Director of EIBIR (the European Institute of Biomedical Imaging Research) and a member of the NAM (National Academy of Medicine) in the US. ...
ByFluidda
PharmAbcine is a clinical stage public company developing next generation IgG based therapeutics to treat cancer, neovascular eye diseases, and vascular related unmet needs. After our Olinvacimab + Merck's Keytruda combo in mTNBC delivered 50% ORR, 67% DCR and clean safety in phase Ib, Phase II multicenter trial is ongoing. ...
Alucent Biomedical, a privately held medical technology company founded to transform the way vascular disease is treated, today announced Venita Chandra, M.D., will join the company’s scientific advisory board. ...
(“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the closing of a $45 million Series B equity financing. ...
End of study brings Robocath closer to commercializing R-One in China in 2023 149 patients enrolled over six months in four Chinese centers Results of first vascular robotics study on this scale in China will be published in March 2023 Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular ...
ByRobocath
A £1.1 million project to develop biodegradable stents for patients with severe vascular disease, which affects around one million people in the UK, has started thanks to Innovate UK funding. ...
With an aging population, there is an increasing incidence of calcified vascular disease in China. According to the Chinese Expert Consensus on the Diagnosis and Treatment of Calcific Coronary Lesions 2021 (Expert Consensus Statement 2021), the risk of developing coronary artery calcification increases with age, with an incidence rate of about 50% in people aged ...
100% clinical success rate: zero complications linked to robot up to 30 days post-procedure >95% technical success rate 84.5% average reduction in physician radiation exposure Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, today presents the results of its R-Evolution ...
ByRobocath
KLISBio is targeting a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed. ...
ByKLISBio
(“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, announced presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting featuring UBX1325 as a potential treatment for diabetic macular edema (DME) and wet age-related macular degeneration (AMD), as well as the ...
“The clinical and preclinical data generated so far suggests that UBX1325, a senolytic small molecule with disease-modifying potential, could improve retinal function through an entirely novel pathway,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. ...
(“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, has completed enrollment for the BEHOLD study, its Phase 2 clinical trial of UBX1325 in patients with diabetic macular edema (DME). ...
KLISBio is leveraging silk as a powerful and biocompatible scaffold material, targeting different clinical indications in the orthopedic, vascular and drug release markets via several technology platforms.”, said Jason Schense, CBO and COO. KLISBio is focused on healing and regenerating human body tissues by developing innovative solutions that solve prominent, unmet ...
ByKLISBio
KLISBio is focused on developing innovative solutions that solve prominent unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug ...
ByKLISBio
“KLISBio is focused on developing innovative solutions to tackle prominent unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained ...
ByKLISBio
” Note: Press release courtesy of Deborah Heart and Lung Center About Deborah Heart and Lung Center Deborah Heart and Lung Center in Browns Mills, NJ is an 89-bed teaching hospital that specializes in the prevention, diagnosis, research, and treatment of heart, lung, and vascular diseases. Founded in 1922, Deborah has been a regional and nationally ...
The innovation achieved so far is truly outstanding and has significant potential to aid clinicians in the treatment of coronary and vascular disease and ultimately bring a better quality of life to patients all over the ...